Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer
T cell exhaustion. Combining a GPR34 antagonist with chemotherapy and surufatinib significantly enhanced anti-tumor responses in preclinical models. These findings identify GPR34 as a promising immune therapeutic target.
Authors
- Chuntao Gao (ORCID: https://orcid.org/0000-0002-9954-8409)
- Xuan Zhou (ORCID: https://orcid.org/0000-0002-1967-3593)
- Tiansuo Zhao (ORCID: https://orcid.org/0000-0003-1631-6299)
- Yuning Song (ORCID: https://orcid.org/0000-0002-3649-962X)
- Xiuchao Wang (ORCID: https://orcid.org/0000-0002-3205-8544)
- Zekun Li (ORCID: https://orcid.org/0009-0007-0957-5803)
- Xiaopeng An
- Xiaofan Guo
- Tianchen Li
- Yiping Zou
- Song Gao
- Bohang Xu
- Yongjie Xie
- Yuxiao Liu
- Jun Yu (ORCID: https://orcid.org/0000-0003-3435-6550)
- Chenyang Meng
- Peijun Xu
- Jihui Hao
- Jing Huang
- Hongwei Wang
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Signal Transduction and Targeted Therapy
- Published
- 2026-04-28
- DOI
- https://doi.org/10.1038/s41392-026-02641-4
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin City
- National Key Research and Development Program of China